Lantern Pharma Q2 2024 GAAP EPS $(0.46) Beats $(0.55) Estimate
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma (NASDAQ:LTRN) reported a Q2 2024 GAAP EPS of $(0.46), beating the analyst consensus estimate of $(0.55) by 16.36%. This represents a 4.55% increase in losses compared to the same period last year.
August 08, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma reported a Q2 2024 GAAP EPS of $(0.46), beating the analyst consensus estimate of $(0.55) by 16.36%. This is a positive surprise for investors, although the losses have increased by 4.55% compared to the same period last year.
The better-than-expected EPS is likely to have a positive short-term impact on the stock price as it indicates the company is performing better than analysts anticipated. However, the increase in losses compared to last year may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100